Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Outcome Technologies (COTI) has completed synthesis of first two new HIV integrase inhibitors under co-development with a pharmaceutical partner.
Subscribe to our email newsletter
Earlier, COTI had entered into this partnership to advance its HIV-1 integrase inhibitor program. As per the agreement, COTI retains all data and intellectual property ownership of the drug candidates including the results of the upcoming in-vitro experiments to be conducted by the codevelopment partner.
COTI said that the next step in the program is for the co-development partner to manage, conduct and fund the agreed upon in-vitro experiments in their evaluation of the compounds. Once these experiments have been completed and the results have been received by COTI, the co-development partner will have an exclusive time period to negotiate a licensing agreement with COTI for the compounds.
Wayne Danter, president and CSO of COTI, said: “HIV/AIDS represents a major unmet medical need and the progress in our program for novel HIV integrase inhibitors brings COTI one step closer to assisting in the fight against this devastating disease.”
Michael Cloutier, CEO of COTI, said: “This is a strategic, cost effective initiative that allows us to rapidly advance our HIV-1 integrase inhibitor program.”